Inhibiting RTK fusions with target specific TKIs has proven to be an effective therapeutic strategy across numerous types of RTK fusion driven cancers – including ALK in ALCL [131], IMT [132] and lung cancer [133], RET in lung and thyroid cancer [134–137], ROS1 in GBM [138], lung cancer [139], and IMT [106], EGFR in lung cancer [117], and NTRK in IMT [140], lung [141], kidney [141], colon [140, 141] and other types of cancer [141]. The gene discussed is EGFR; the disease is cancer.